| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |


( Laboratoires de Recherche, Institut du Cancer de Montréal, Hôpital Notre-Dame et Université de Montréal, Montréal, Canada)
Three different cellular populations can be distinguished in preneoplastic liver parenchyma on the basis of ribonucleic acid staining with the basic dye toluidine blue: hypobasophilic, basophilic, and hyperbasophilic cells, which correspond respectively to (a) degenerating cells, (b) regenerating cells, and (c) cells apparently undergoing the neoplastic transformation.
Quantitative determinations of the incidence of mitoses in these different populations reveal that the mitotic activity in hyperbasophilic regions is intermediate between the values obtained in basophilic parenchyma and the high activities observed in hepatomas. These results support the view that hyperbasophilic regions represent a transition between hyperplasia and neoplasia, i.e., the actual sites of neoplastic transformation in preneoplastic liver parenchyma.
Studies on cytologic and histochemical changes occurring during preneoplasia reveal that alterations in the metabolism of nucleic acids are among the first modifications occurring in sites of neoplastic transformation and suggest that they may represent initiating steps in tumor formation.
* This investigation was supported by a grant from the National Cancer Institute of Canada to Dr. A. Cantero, Director of the Research Laboratories. Preliminary reports of this work were presented at the Fifth Canadian Cancer Research Conference held in Honey Harbour in June, 1962 (8), and at the 54th Annual Meeting of the American Association for Cancer Research held in Toronto in May, 1963 (11).
Research Scientist of the National Cancer Institute of Canada.
Fellow of the Cancer Research Society.
This article has been cited by other articles:
![]() |
N. Bhattacharjee, S. Pathak, and A. R. Khuda-Bukhsh Amelioration of Carcinogen-Induced Toxicity in Mice by Administration of a Potentized Homeopathic Drug, Natrum Sulphuricum 200 Evid. Based Complement. Altern. Med., June 19, 2007; (2007) nem067v1. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |